Parkinson's vaccine trial aims to slow disease progression
NCT ID NCT06015841
First seen Nov 21, 2025 · Last updated Jun 17, 2026 · Updated 26 times
Summary
This study tests a vaccine called ACI-7104.056 in 150 people with early-stage Parkinson's disease. The goal is to see if it is safe and helps the body fight a protein linked to Parkinson's. Participants must already be on stable low-dose levodopa. This is not a cure, but may help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital De La Santa Creu I Sant Pau
Barcelona, Spain
-
Hospital Universitari Vall D Hebron
Barcelona, Spain
-
Hospital Universitario De La Princesa
Madrid, Spain
-
Hospital Universitario Puerta De Hierro De Majadahonda
Majadahonda, Spain
-
Hospital Universitario Quironsalud Madrid
Pozuelo de Alarcón, Spain
-
Katholisches Klinikum Bochum GmbH
Bochum, Germany
-
King's College Hospital NHS Foundation Trust
London, United Kingdom
-
Northern Care Alliance NHS Foundation Trust
Salford, United Kingdom
-
Paracelsus-Kliniken Deutschland GmbH & Co. KGaA
Kassel, Germany
-
Policlinica Gipuzkoa
Donostia / San Sebastian, Spain
-
Re:Cognition Health Limited
London, United Kingdom
-
University Medical Centre Schleswig-Holstein
Kiel, Germany
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.